Security key
471871111
Jasper Therapeutics, Inc. - *W EXP 09/24/202 (JSPRW)
CUSIP: 471871111
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / *W EXP 09/24/202
- Total 13F shares
- 2,958,733
- Total 13F value
- $538,489
- Share change
- +2,415
- SEC-reported price per share
- $0.18
- Number of holders
- 4
- Value change
- +$15,712
- Number of buys
- 1
- Number of sells
- 3
Report period
Q1 2024
Institutions
4
Top holders
4
JSPRW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Jasper Therapeutics, Inc. SEC filings
Jasper Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 471871111
Recent filing periods:
Ownership snapshot
Top reported holders of JSPRW - Jasper Therapeutics, Inc. - *W EXP 09/24/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Velan Capital Investment ...
Disclosed value leader
Ally Bridge Group (NY) LLC
Comparable rows
0/15
Latest evidence
08 Feb 2024
3/4/5
13F
Highest disclosed value: $28,871,522
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Ally Bridge Group (NY) LLC has the largest disclosed position value at $28.87M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ally Bridge Group (NY) LLC's linked filing trail.
Disclosed position value
Top 5
Velan Capital Investment Manageme...
$18.57M
Carlyle Group Inc.
$13.81M
Qiming U.S. Healthcare Fund II, L.P.
$5.53M
ROCHE HOLDING LTD
$2.95M
Amplitude Healthcare Holdings LLC
$1.49M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP |
3/4/5
13F
10%+ Owner · Company
|
—
denominator unverified
|
$18,568,073
1,433,828 shares
|
— | 08 Feb 2024 |
| Carlyle Group Inc. |
3/4/5
13F
Former 10% Owner · Company
|
—
denominator unverified
|
$13,807,148
1,066,189 shares
|
— | 08 Feb 2024 |
| Qiming U.S. Healthcare Fund II, L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$5,525,844
8,519,648 shares
|
— | 27 Jan 2023 |
| ROCHE HOLDING LTD |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$2,950,874
4,549,606 shares
|
— | 25 Jan 2023 |
| Amplitude Healthcare Holdings LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,491,780
2,300,000 shares
|
— | 24 Sep 2021 |
| Abingworth LLP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
78,045 shares
|
— | 21 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
2,958,733
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q2 2026 Across Filers
Q2 2026 holders
7
Q1 2024 holders
4
Holder diff
-3
| Investor | Q2 2026 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q2 2026 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend